

ASTELLAS INDEPENDENT MEDICAL EDUCATION

Astellas has identified therapeutic area independent healthcare education gaps that align with our business needs and seek to support educational activities in these areas which will impact HCPs' knowledge, competence, and application and positively contribute to improving health care for patients.

Note: Astellas may also periodically post unique *Call for Grant Applications* on the AGMS homepage and the Alliance for CEhp to seek out additional educational activities.

Therapeutic Area	Independent Healthcare Gaps
Cardiovascular	<ul style="list-style-type: none"> • Application of appropriate imaging modalities for patient risk assessment • Appropriate use of pharmacologic stress agents with cardiovascular imaging modalities • Effective patient communication /engagement related to imaging options, risk assessment and coordination of care
Infectious Disease - Fungal	<ul style="list-style-type: none"> • Understanding and application of susceptibility testing • Understanding the role and application of PK/PD in management and clinical outcomes in fungal infections • Management of mold infections in immunocompromised patients • Effective patient communication /engagement related to risk assessment, prophylaxis and coordination of care
Oncology - AML	<ul style="list-style-type: none"> • Rapidly evolving landscape of AML genomics and pathways (e.g., FLT3 and AXL, resistance) • Treatment strategies and therapeutic options for first line relapsed AML • Treatment strategies and therapeutic options for AML in the elderly
Oncology - Breast	<ul style="list-style-type: none"> • Evolving Triple Negative Breast Cancer (TNBC) molecular biology and treatment landscape • Knowledge and awareness of androgen receptor signaling pathway inhibition in TNBC pathogenesis • Safety/efficacy and clinical application of newly approved and emerging novel agents • Patient perspective and treatment expectations/barriers and burden of disease/adverse consequences of therapy
Oncology - Lung	<ul style="list-style-type: none"> • Evolving landscape of lung cancer biology (e.g., biomarkers, drug resistance, impact of ethnicity) • Choose appropriate treatment approaches related to the patient's lung cancer biology (e.g., biomarkers, etc.) • Effective strategies to mitigate the cutaneous toxicities associated with EGFR TKI agents • Effective patient communication /engagement
Oncology - Prostate	<ul style="list-style-type: none"> • Evolving landscape of prostate cancer biology (e.g., biomarkers, drug resistance, impact of ethnicity) • Effective patient communication /engagement • Combination and sequencing of approved and emerging agents • Shared decision making – enhancing HCP and patient interaction • Increasing awareness in treatment disparities in minority populations
Transplant/Immunology	<ul style="list-style-type: none"> • Long-term outcomes in solid organ transplantation • Maintenance of appropriate immunosuppression levels • Effective patient communication /engagement
Urology	<ul style="list-style-type: none"> • Differentiate mechanism of action for current therapeutic options • Appropriate OAB evaluation/screening and follow-up • Low adherence/persistence by patients to therapeutic options • Effective patient communication /engagement

Reviewed: 7-16-2013

Updated 8-20-15